synthetic semaglutide Peptide mapping analysis of and liraglutide for generic development of drugs originating from recombinant DNA technology Semaglutide | 910463-68-2

Using medication beyond its recommended in-use period may result in reduced efficacy or increased risk of contamination

The DECLARE-TIMI 58 trial enrolled a majority of patients who did not have established atherosclerotic cardiovascular disease (ASCVD), and did not show significant reduction in MACE.19 This may imply the cardioprotection offered by SGLT2 inhibitors is less evident in such a group of patients .18 However, analysis from the EMPA-REG OUTCOME trial reported consistent benefits regardless of baseline risks and prior history.21 Neither of these trials was designed to investigate HF outcomes, but they illustrated the value in identifying patient subgroups that benefit most from SGLT2 inhibitor treatment

doi:10.1172/JCI88871 Weinheimer EM, Sands LP, Campbell WW

The company said it has more retatrutide trials planned this year

doi: 10.1016/j.jdiacomp.2012.08.001